Codexis (CDXS) Competitors

Codexis has a net margin of -39.55% compared to Ginkgo Bioworks' net margin of -259.96%. Ginkgo Bioworks' return on equity of -60.27% beat Codexis' return on equity.

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 2 mentions for Codexis. Codexis' average media sentiment score of 1.18 beat Ginkgo Bioworks' score of 0.25 indicating that Codexis is being referred to more favorably in the media.

Codexis presently has a consensus price target of $6.50, indicating a potential upside of 392.42%. Ginkgo Bioworks has a consensus price target of $6.33, indicating a potential downside of 40.18%. Given Codexis' stronger consensus rating and higher possible upside, equities analysts clearly believe Codexis is more favorable than Ginkgo Bioworks.

Codexis has higher earnings, but lower revenue than Ginkgo Bioworks. Codexis is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

78.5% of Codexis shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.5% of Codexis shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Codexis has a net margin of -39.55% compared to Pacific Biosciences of California's net margin of -82.49%. Codexis' return on equity of -74.36% beat Pacific Biosciences of California's return on equity.

Pacific Biosciences of California presently has a consensus price target of $1.71, suggesting a potential upside of 5.71%. Codexis has a consensus price target of $6.50, suggesting a potential upside of 392.42%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Pacific Biosciences of California.

In the previous week, Codexis had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 2 mentions for Codexis and 1 mentions for Pacific Biosciences of California. Codexis' average media sentiment score of 1.18 beat Pacific Biosciences of California's score of 1.03 indicating that Codexis is being referred to more favorably in the news media.

Pacific Biosciences of California has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

78.5% of Codexis shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 3.5% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Codexis has lower revenue, but higher earnings than Pacific Biosciences of California. Codexis is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

In the previous week, Alpha Teknova had 1 more articles in the media than Codexis. MarketBeat recorded 3 mentions for Alpha Teknova and 2 mentions for Codexis. Codexis' average media sentiment score of 1.18 beat Alpha Teknova's score of 0.75 indicating that Codexis is being referred to more favorably in the news media.

Alpha Teknova has a net margin of -38.37% compared to Codexis' net margin of -39.55%. Alpha Teknova's return on equity of -24.94% beat Codexis' return on equity.

Alpha Teknova currently has a consensus target price of $8.00, suggesting a potential downside of 14.26%. Codexis has a consensus target price of $6.50, suggesting a potential upside of 392.42%. Given Codexis' higher probable upside, analysts plainly believe Codexis is more favorable than Alpha Teknova.

Alpha Teknova has higher earnings, but lower revenue than Codexis. Alpha Teknova is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Alpha Teknova has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 13.2% of Alpha Teknova shares are held by insiders. Comparatively, 3.5% of Codexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Codexis currently has a consensus target price of $6.50, indicating a potential upside of 392.42%. Simulations Plus has a consensus target price of $17.25, indicating a potential downside of 6.55%. Given Codexis' stronger consensus rating and higher possible upside, research analysts plainly believe Codexis is more favorable than Simulations Plus.

Codexis has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

In the previous week, Simulations Plus had 3 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Simulations Plus and 2 mentions for Codexis. Codexis' average media sentiment score of 1.18 beat Simulations Plus' score of 0.93 indicating that Codexis is being referred to more favorably in the media.

78.5% of Codexis shares are owned by institutional investors. Comparatively, 78.1% of Simulations Plus shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Comparatively, 19.1% of Simulations Plus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Codexis has higher earnings, but lower revenue than Simulations Plus. Codexis is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Simulations Plus has a net margin of 9.88% compared to Codexis' net margin of -39.55%. Simulations Plus' return on equity of 13.50% beat Codexis' return on equity.